Interview: AstraZeneca’s Pangalos On Landmark DAPA-HF Results

The stand-out session at this year’s European Society of Cardiology Congress in Paris, France was the presentation of results from AstraZeneca PLC’s DAPA-HF Phase III study of Forxiga/Farxiga (dapagliflozin) in heart failure with reduced ejection fraction. The study paves the way for the SGLT-2 inhibitor’s approval – likely in the first half of 2020 – to treat heart failure in both diabetic and non-diabetic patients.